-73%

est. 2Y upside i

HealthcareSeries A

Life's better without allergies

Rank

#2020

Sector

Healthcare & Medical

Est. Liquidity

~5Y

Data Quality

Data: Medium

Wyndly, a Series A company in the growing telehealth allergy treatment market, presents a moderate upside opportunity.

Last updated: March 10, 2026

Bull (15%)+300%

Wyndly successfully expands its market penetration by leveraging its telehealth model and strong patient experience, potentially securing broader insurance partnerships. This could drive significant revenue growth, reaching $50M+ ARR and justifying a $100M+ valuation by attracting a larger Series B or C round or an acquisition by a larger healthcare provider.

Base (55%)+50%

Wyndly continues to grow steadily within its niche, maintaining its current revenue model and competitive position against other telehealth providers. Revenue grows to approximately $15-20M ARR, leading to a modest valuation increase to around $37.5M, allowing for a follow-on funding round but limited immediate liquidity for common shareholders.

Bear (30%)-80%

Increased competition from well-funded incumbents or direct telehealth rivals, coupled with regulatory challenges or slower-than-expected customer acquisition, stifles growth. This could lead to a down round or difficulty raising further capital, reducing the valuation to $5M and significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Investors hold $2.12M in liquidation preferences, representing 8.48% of the assumed $25M current valuation.

Dilution Risk

high

As a Series A company, Wyndly will almost certainly require multiple additional funding rounds (Series B, C, etc.) to scale, which will lead to significant dilution for common shareholders.

Secondary Liquidity

none

Given its early stage and size, there is currently no active secondary market or tender offers for Wyndly's equity.

Questions to Ask at the Interview

Strategic questions based on Wyndly's data — designed to show you've done your homework.

  • 1

    “Given the competitive landscape with players like Curex, Nectar, and Aspire Allergy, what are Wyndly's key differentiators beyond convenience, and how do you plan to maintain a competitive edge and market share over the next 2-3 years?”

  • 2

    “With a hybrid revenue model and some insurance billing for testing, how does Wyndly plan to navigate the complexities of insurance reimbursement for SLIT treatment to potentially broaden access and accelerate growth?”

  • 3

    “As a Series A company, what is the anticipated timeline for future funding rounds, and how is the company planning to manage potential dilution for early employees holding equity?”

Community

Valuation Sentiment

Our model estimates -73% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.